Skip to main content

Department of Psychiatry

and Behavioral Sciences

Explore INSPIRE

Research Studies

INSPIRE Clinic

RENEW-Scz-1: A New Medication for Adults with Schizophrenia	Stanford researchers are looking for adults with schizophrenia who are taking medicine to manage their symptoms, who are willing to take an additional placebo or investigational drug while continuing to take their usual medicine. The study will test if the investigational medicine can help people manage their weight and improve their thinking and memory. To learn more about the study: https://e.lilly/47BnTr6 or contact wakeham@stanford.edu
Brief online study for anyone with a psychosis diagnosis!	We are looking for anyone with a psychosis related diagnosis to take part in a very brief (~5 minute) research questionnaire examining physiological symptoms and feelings of social safety, with additional paid study phases for those interested. Anyone with psychosis is eligible! Click here to take the survey or find out more about the study, or contact summerrd@stanford.edu
Compassion Focused Therapy Techniques & Heart Rate Variability in Psychosis	We are conducting a brief study to better understand how compassion-focused therapy techniques may affect heart rate in individuals with psychosis-related diagnoses. Anyone with a psychosis related diagnosis aged over 18 can participate! What participation involves: One in-person visit (approximately 60–70 minutes) Wearing a comfortable chest strap to monitor heart rate Completing guided imagery and breathing exercises Answering questionnaires and providing feedback If you would like further information or you’re interested in taking part please contact us at summerrd@stanford.edu.
CN012-0077 An Open-Label Study to evaluate the efficacy and tolerability of Xanomeline/Trospium in First Episode/Early Phase Schizophrenia Patients	Stanford researchers are recruiting adults with schizophrenia in the early phase of illness for a clinical trial. This is an open label study of the treatment satisfaction, efficacy and tolerability of xanomeline/ trospium (Cobenfy) in adults diagnosed with schizophrenia in the early phase of illness. Recruitment is based on: Insufficient efficacy of previous antipsychotic OR Due to dissatisfaction with treatment as a result of unacceptable side effects on previous antipsychotic/patient choice If you would like further information or you’re interested in taking part please contact us at wakeham@stanford.edu. Learn More
Brain Stimulation to the Hippocampus in Schizophrenia	Stanford researchers are recruiting adults with schizophrenia for a study to understand whether hippocampal activity in schizophrenia can be systematically affected by non-invasive brain stimulation techniques like transcranial magnetic stimulation (TMS). This study will investigate the use of connectivity-guided theta burst brain stimulation to specifically target hippocampal function in schizophrenia. Learn More
Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling	Stanford researchers are recruiting adult participants diagnosed with bipolar disorder, major depressive disorder, and/or schizophrenia for a study evaluating the effect of ketogenic metabolic therapy on the quality of life in serious mental illness schizophrenia, bipolar disorder, and major depressive disorder. If you are interested in participating, please contact Sarah Drobny at sarah.drobny@stanford.edu. Learn More
Enlighten Youth: Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder	Stanford researchers are recruiting teen participants with schizophrenia, schizophreniform, or bipolar disorder who are either currently treated with olanzapine, or if treated with another antipsychotic, the subject has had an inadequate response. The purpose of this study is to find out whether a study drug, LYVALBI (an approved FDA medication of olanzapine/samidorphan), is safe and effective in reducing weight gain in teen participants taking antipsychotics. A 52 week trial may be optionally extended to study long term safety. If you would like further information or you’re interested in taking part please contact us at inspire-research@stanford.edu. Learn More
Epi-Cal Beehive: California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis	Stanford researchers are working with UC Davis to recruit patients with schizophrenia to build a California early psychosis network using a core assessment battery of surveys delivered by iPad during a normal clinical visit. The aim of this study is to measure the Duration of Untreated Psychosis (DUP) and hopefully standardize best practices for first onset of psychosis throughout the state in community settings. The proposed California network will contribute systematically collected outcomes data from community and university early psychosis clinics, to enhance the development of a national early psychosis network, supported by the NIMH EPINET program. If you would like further information or you're interested in taking part please contact your clinician during your regular INSPIRE appointment. Learn More

Expand All

pET Scan: Imaging Synapses With [11C] UCB-J in the Human Brain	Stanford researchers are recruiting healthy controls and participants with an onset of schizophrenia within the last 5 years for a basic research study involving a pET scan. The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer [11C]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. We are measuring the synaptic density in the living human brain and exploring the theory that the pathogenic process of schizophrenia is the over-exuberant elimination of neural synapses during development. This study is currently closed for enrollment.
Peripheral Immune System in Individuals With Schizophrenia	Stanford researchers are recruiting participants who are already participating in Imaging Synapses With [11C] UCB-J in the Human Brain for participation in basic research exploring the role of the complement immune system in the development of schizophrenia. The purpose of this study is to compare immune system proteins found in the blood of patients with and without psychosis, to determine if functional differences are present that may shed light on biochemical and genetic differences in schizophrenia. Participants would do a single blood draw, usually done during the imaging scan. This study is currently closed for enrollment.
IMPACT-TD: A prospective multicenter study to characterize the natural history of tardive dyskinesia (TD) and investigate the real world effectiveness of deutetrabenazine on the multidimensional impact of TD	Stanford researchers are participating in a registry study to follow the natural history of tardive dyskinesia (TD) and optionally to investigate the real-world effectiveness of deutetrabenazine (FDA-approved medicine AUSTEDO) on treating TD. This study is currently closed for enrollment.
Culturally Informed Therapy Groups	We invite you to participate in a research study aimed at improving family relations and mental health symptoms. Groups will be offered virtually and in person. Dates/Times TBD. Psychotherapy groups consist of 5 modules: Family/Collectivism Psychoeducation Religion/Spirituality/Philosophical Beliefs Communication Skills Problem-Solving Skills Each of these modules consists of 3 sessions and each session is one hour, once a week. This study is currently closed for enrollment.

For more information on national research, please visit: